

Resource Summary Report

Generated by [dkNET](#) on Sep 2, 2026

NCI-H2073

RRID:CVCL_1521

Type: Cell Line

Proper Citation

RRID:CVCL_1521

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1521

Proper Citation: RRID:CVCL_1521

Description: Cell line NCI-H2073 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Lung adenocarcinoma

Defining Citation: [PMID:1311061](#), [PMID:8806092](#), [PMID:22460905](#), [PMID:22961666](#), [PMID:24297535](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:26589293](#), [PMID:28196595](#), [PMID:29681454](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31803961](#)

Comments: Population: Caucasian., Part of: MD Anderson Cell Lines Project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: NCI-H2073

Synonyms: H2073, H-2073, NCIH2073

Cross References: CLO:CLO_0008045, EFO:EFO_0006670, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ATCC:CRL-5918, BioSample:SAMN03473292, BioSample:SAMN10989581, cancercellines:CVCL_1521, Cell_Model_Passport:SIDM00757, Cosmic:687811, Cosmic:903612, Cosmic:1146899, Cosmic:1870268, DepMap:ACH-000590, EGA:EGAS00001000610, GEO:GSM253368, GEO:GSM513954, GEO:GSM514339, GEO:GSM794346, GEO:GSM888478, GEO:GSM1374719, IARC_TP53:512, LiGeA:CCLE_043, LINC_S_LDP:LCL-1649,

PharmacDB:NCIH2073_1061_2019, Progenetix:CVCL_1521, Wikidata:Q54907911

ID: CVCL_1521

Record Creation Time: 20220427T220838+0000

Record Last Update: 20260829T234731+0000

Ratings and Alerts

No rating or validation information has been found for NCI-H2073.

No alerts have been found for NCI-H2073.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 7 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Savoca A, et al. (2026) Preclinical to Clinical Translation of Pharmacokinetic-Pharmacodynamic Relationship in EGFR Exon20Ins Mutations: A Modeling Framework for Irreversible Inhibitors. *Molecular cancer therapeutics*, 25(7), 1157.

Galan-Cobo A, et al. (2025) KEAP1 and STK11/LKB1 alterations enhance vulnerability to ATR inhibition in KRAS mutant non-small cell lung cancer. *Cancer cell*, 43(8), 1530.

Pagliarini RA, et al. (2025) STX-721, a Covalent EGFR/HER2 Exon 20 Inhibitor, Utilizes Exon 20-Mutant Dynamic Protein States and Achieves Unique Mutant Selectivity Across Human Cancer Models. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 31(14), 3002.

Pelos G, et al. (2024) Fast proliferating and slowly migrating non-small cell lung cancer cells are vulnerable to decitabine and retinoic acid combinatorial treatment. *International journal of cancer*, 154(6), 1029.

Yenerall P, et al. (2020) RUVBL1/RUVBL2 ATPase Activity Drives PAQosome Maturation, DNA Replication and Radioresistance in Lung Cancer. *Cell chemical biology*, 27(1), 105.

LeBoeuf SE, et al. (2020) Activation of Oxidative Stress Response in Cancer Generates a Druggable Dependency on Exogenous Non-essential Amino Acids. *Cell metabolism*, 31(2), 339.

Updegraff BL, et al. (2018) Transmembrane Protease TMPRSS11B Promotes Lung Cancer Growth by Enhancing Lactate Export and Glycolytic Metabolism. *Cell reports*, 25(8), 2223.